Drug ID: 2d00000014
Drug Name: Belimumab
Generic Names: Benlysta
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The recommended dose is 10 mg/kg at two-week intervals for the first three doses and at four-week intervals thereafter.
Recommended In: This medication is a monoclonal antibody, prescribed for active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. It blocks the activity of a certain protein in people with SLE. It may not work as well to treat African Americans who have SLE.
Directions For Use: It comes as a powder for injection (diluted with fluid), to be administered by a healthcare provider into the vein.
Storage: Store it in refrigerator (2 to 8°C). Do not freeze it.
Dosage Forms: Reconstituted vials for Intravenous injection
Side Effects: Most Common - Nausea, diarrhea, fever, inflammation of pharynx, lungs, sleeplessness, pain in extremity, depression and headache.
Seriois Effects- Fatal anaphylaxis.
In Case of Overdose: There is no clinical experience with overdosage of Belimumab.
Avoid If: Caution should be exercised in patients with history of cancer, chronic infection, depression, mental illness, any allergy, infection, flu-like symptoms, children, during pregnancy and breastfeeding.
In depression patients, this medication may increase the risk of suicidal thoughts; if it is so consult with your doctor.
Avoid live vaccination during the treatment period.
Contraindicated in patients with life-threatening severe allergic reactions.
Drug Interaction: No significant drug interaction is observed yet.